EMA Recommends Granting a Marketing Authorisation for Vimseltinib By Ogkologos - September 5, 2025 253 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults with symptomatic tenosynovial giant cell tumour Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Ibrutinib July 15, 2022 Opinion: ‘Beating cancer means beating it for everyone’ January 29, 2021 Mental Health Awareness for Health Care Providers May 21, 2021 Her Cancer Surgery Was Postponed Due To The COVID-19 Pandemic —... July 7, 2020 Load more HOT NEWS FDA Proposes Changes to Mammography Standards to Inform Women About Breast... Cancer Won’t Wait: “I prayed she would see her daughter start... Why the voices of people affected by cancer are critical to... Penn State Researchers Working on Amazon Alexa Skill for Metastatic Breast...
